# 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

> **NCT06864988** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **4D Molecular Therapeutics** · enrollment: 480 (estimated)

## Conditions studied

- Macular Neovascularization Secondary to Age-Related Macular Degeneration

## Interventions

- **BIOLOGICAL:** 4D-150 IVT (3E10 vg/eye)
- **BIOLOGICAL:** EYLEA® (aflibercept) Injection 2 mg (0.05mL)

## Key facts

- **NCT ID:** NCT06864988
- **Lead sponsor:** 4D Molecular Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-03
- **Primary completion:** 2027-06
- **Final completion:** 2028-06
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06864988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06864988, "4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06864988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*